援助如何运作

通过无与伦比的全方位服务便利性,简化患者的专业药房体验

  • 覆盖率验证代码

    1. 检查您的保险范围/福利验证

    我们的专业出纳员团队会找到最佳的保险途径,以最大程度地减少自付费用。

  • 将处方转移至 AmeriPharma - 图片

    2. 将处方转移到 AmeriPharma®

    我们与您之前的药房或处方人员合作来处理您的处方,使过渡变得快速而简单。

  • 图标 - Eligard 共付额援助流程

    3. 事先授权

    我们的专家团队将在 24 至 72 小时内获得您保险公司的批准。

  • Eligard 自付额财务援助图标

    4. 共付额援助和经济援助

    我们确保患者获得经济援助,并降低共付额、自付费用和高额免赔额。迄今为止,AmeriPharma® 专科护理已为患者争取到 1TP4.4755 亿美元的经济援助。

  • 护理标志

    5. 必要时的护理协调

    AmeriPharma® 在安排和协调我们的专业护士为您进行家庭输液时,会将您的日程安排和家庭环境放在首位。

  • 配送协调 - 图片

    6. 交付协调

    药品始终严格遵守运输的具体要求。次日或隔夜冷链配送将根据您的时间安排进行协调。

What Is Eltrombopag?

Eltrombopag (brand name Promacta) is an oral medication prescribed to increase platelet counts in people with certain blood disorders, including chronic immune thrombocytopenia (ITP). Platelets are blood cell fragments that help form clots and stop bleeding.

In 2008, eltrombopag (Promacta) received approval from the Food and Drug Administration (FDA) to treat certain adults with chronic immune thrombocytopenia (ITP). The FDA later expanded its approved uses to include other conditions associated with low blood cell counts. Common side effects of this drug may include nausea, headache, diarrhea, urinary tract infections, upper respiratory tract infections, and fever.

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/pharmacist.jpg
https://ameripharmaspecialty.com/wp-content/uploads/2024/02/block_image_1.jpg

Eltrombopag (Promacta): FDA-Approved Uses

The FDA has approved eltrombopag (Promacta) for several conditions associated with low platelet or blood cell counts, including persistent or chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older. Its approved uses include:

  • To treat adults and children aged 1 year and older with persistent or chronic ITP who have not responded adequately to corticosteroids, 免疫球蛋白, or splenectomy. It should be used only in patients whose condition and degree of thrombocytopenia increase their risk of bleeding.
  • To treat low platelet counts in patients with chronic hepatitis C who need to start and maintain interferon-based therapy.
  • As first-line treatment in combination with standard immunosuppressive therapy for adults and children aged 2 years and older with severe aplastic anemia (SAA).
  • To treat patients with severe aplastic anemia (SAA) who have not responded adequately to immunosuppressive therapy.

Promacta (eltrombopag) is not recommended to treat patients with myelodysplastic syndromes (MDS).

作用机制(MOA)

Eltrombopag (Promacta) belongs to the class of medicines called thrombopoietin receptor (TPO) agonists. It activates thrombopoietin receptors in the bone marrow, stimulating the production of platelets.

By increasing platelet production, eltrombopag (Promacta) can help reduce the risk of bleeding in patients with low platelet counts. In patients with severe aplastic anemia, it may also improve red and white blood cell counts.

How Eltrombopag Copay Assistance Works

AmeriPharma® 特药药房减轻了患者及其家人的经济负担

  • 高级软件图标

    先进的软件可以定位资金来源,为您匹配高额的基金会项目

  • 共付额和经济援助

    我们的一位共付额援助专家将协助您完成申请流程

  • 资金图标

    自动更新信息将发送给您和您的医生,告知您资金状况

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/Mask-Group-45-1.jpg

The dosage of eltrombopag (Promacta) varies depending on the condition being treated, the patient’s age, liver function, and response to treatment. Below are the recommended dosages for adult and pediatric patients indicated by the FDA.

Dosage for Persistent or Chronic ITP

The recommended starting dose for most adults and children aged 6 years and older with persistent or chronic ITP is 50 mg orally once daily. For children aged 1 to 5 years, the recommended starting dose is 25 mg once daily.

Dosage for Chronic Hepatitis C-associated Thrombocytopenia

For patients with chronic hepatitis C-associated thrombocytopenia, the recommended starting dose of Promacta is 25 mg orally once daily. The dose may be adjusted based on platelet counts and treatment response.

First-line Severe Aplastic Anemia

The dosage of Promacta in combination with standard immunosuppressive therapy for the treatment of severe aplastic anemia is as follows:

  • For pediatric patients aged 2 to 5 years: Promacta orally once daily at 2.5 mg/kg
  • For pediatric patients aged 6 to 11 years: one 75 mg tablet once a day
  • For patients aged 12 years and older: 150 mg orally once daily, concurrently with standard immunosuppressive therapy.

Refractory Severe Aplastic Anemia

The recommended starting dosage for patients with refractory severe aplastic anemia is 50 mg orally once daily. The dose may be adjusted based on blood counts and treatment response.

Patients with liver problems or East- or Southeast-Asian ancestry may require a lower starting dose of Promacta. However, dosage adjustments vary depending on the condition being treated. Your healthcare provider will determine the appropriate dose and adjust it based on your response to treatment.

Eltrombopag Side Effects

常见的副作用包括:
  • Low levels of red blood cells (贫血)
  • 恶心
  • 发烧
  • Abnormal liver function tests
  • 咳嗽
  • 感觉疲倦
  • 头痛
  • 腹泻
  • 皮疹
  • Skin discoloration (hyperpigmentation)

 

严重的副作用包括:
  • 严重过敏反应
  • Liver damage (hepatotoxicity)
  • High platelet counts and an increased risk of blood clots
  • Worsening liver function in patients with chronic hepatitis C who receive Promacta with interferon and ribavirin
  • Increased risk of cataracts or worsening progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML)

接受保险

我们接受 Medicare、跨州 Medicaid、Medi-Cal、Blue Shield 以及大多数私人保险。请致电我们,了解更多您的保险信息。

  • 网站页脚显示 Medicare 标志。.
  • Medicaid 标志
  • 蓝十字 Blue Shield 标志

几分钟内即可开始

填写您的信息,我们的一位专家将尽快给您回电。

您能节省多少钱?

填写此表格,最高可节省 100%!

符合 HIPAA 标准